david+mendelowitz Available Technologies | The George Washington University

Search Results - david+mendelowitz

3 Results Sort By:
Intranasal leptin to treat opioid-induced respiratory depression (OIRD) in obese patients
­Respiratory depression is the leading cause of morbidity and mortality associated with opioids. Patients with obesity experience pain and need opioids more frequently than normal-weight individuals. Chronic consumption of opioids is associated with addiction, physical dependence, and tolerance. Tolerance leads to requirement of higher doses of...
Published: 4/5/2022   |   Inventor(s): David Mendelowitz, Vsevolod Polotsky, Carla Freire
Category(s): Technology Classifications > Therapeutics
Intranasal Oxytocin to Treat Heart Failure
Heart failure (HF) results in imbalance of the cardiac autonomic system, i.e. increased sympathetic activity and decreased parasympathetic activity. The present therapies for heart failure only decrease sympathetic activity and have many side effects. There is no drug or device that restores parasympathetic activity. GW researchers found a new method...
Published: 1/13/2022   |   Inventor(s): Matthew Kay, David Mendelowitz, Jhansi Dyavanapalli, Kara Garrott, Gregory Trachiotis
Category(s): Technology Classifications > Therapeutics > Proteins and Peptides
Intranasal Oxytocin Therapy for Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a health risk that occurs in 24% of males and 9% of females in the United States. OSA can lead to several cardiovascular diseases including hypertension, arrhythmia, and stroke. Continuous positive airway pressure (CPAP) treatments often fail due to low compliance. GW Researchers developed an intranasal oxytocin administration...
Published: 1/13/2022   |   Inventor(s): David Mendelowitz, Heather Jameson, Vivek Jain, Jay Kimbro
Category(s): Technology Classifications > Medical Devices > Cardiology, Technology Classifications > Therapeutics > Proteins and Peptides